Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Non-Current Debt (2017 - 2026)

Bioceres Crop Solutions' Non-Current Debt history spans 10 years, with the latest figure at $54.1 million for Q1 2026.

  • On a quarterly basis, Non-Current Debt fell 28.53% to $54.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $54.1 million, a 28.53% decrease, with the full-year FY2025 number at $43.7 million, up 3.78% from a year prior.
  • Non-Current Debt hit $54.1 million in Q1 2026 for Bioceres Crop Solutions, up from $43.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for BIOX hit a ceiling of $75.7 million in Q1 2025 and a floor of $42.1 million in Q2 2024.
  • Historically, Non-Current Debt has averaged $58.4 million across 5 years, with a median of $57.4 million in 2023.
  • Biggest five-year swings in Non-Current Debt: surged 54.57% in 2022 and later plummeted 30.6% in 2024.
  • Tracing BIOX's Non-Current Debt over 5 years: stood at $74.2 million in 2022, then dropped by 18.21% to $60.7 million in 2023, then plummeted by 30.6% to $42.1 million in 2024, then rose by 3.78% to $43.7 million in 2025, then rose by 23.81% to $54.1 million in 2026.
  • Business Quant data shows Non-Current Debt for BIOX at $54.1 million in Q1 2026, $43.7 million in Q2 2025, and $75.7 million in Q1 2025.